title: Economic analysis of newer antiepileptic drugs.
abstract: In the last 20 years, several second-generation antiepileptic drugs (AEDs) have been marketed. These newer drugs are expensive and have no established superiority over the first-generation compounds in terms of efficacy when used as monotherapy. A systematic review of economic studies dealing with the newer AEDs has been performed to put these drugs in a wider perspective. A number of economic analysis studies of second-generation AEDs have examined these compounds as monotherapy or adjunctive therapy. Almost all monotherapy studies showed newer AEDs as having similar effectiveness but significantly higher acquisition costs than first-generation drugs. The evidence from adjunctive therapy studies was more conflicting. Lamotrigine appeared to be a cost-effective drug when higher thresholds were used, or when savings were defined by the cost of surgery. Levetiracetam also appeared to be cost effective when the costs of surgical investigation were discounted.In a decision model that included quantification of the uncertainty associated with the decision regarding the cost effectiveness of AEDs, second-generation drugs used as monotherapy for newly diagnosed partial epilepsy produced similar benefits but were more expensive than older drugs. The newer AEDs were more effective but more expensive than existing monotherapies in patients with refractory partial epilepsy, but may be cost effective at higher thresholds, and continue to be cost effective in patients responding to the assigned drug. In patients with newly diagnosed generalized epilepsy, valproate was more cost effective than lamotrigine.The results of current economic studies are difficult to assess and compare because of a number of methodological drawbacks. Future studies should be implemented using a standardized approach to define the costs and outcomes of representative cohorts of patients with newly diagnosed epilepsy recruited from different countries and followed prospectively.
authors.affiliation: Laboratorio di Malattie Neurologiche, Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy. beghi@marionegri.it
authors.forename: Ettore
authors.initials: E
authors.lastname: Beghi
authors.forename: Lucia
authors.initials: L
authors.lastname: Atzeni
authors.forename: Livio
authors.initials: L
authors.lastname: Garattini
mesh_terms: D000927:Anticonvulsants / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis / Q000191:economics; D004827:Epilepsy / Q000188:drug therapy* / Q000191:economics; D006801:Humans
chemical_list: D000927:Anticonvulsants
references.citation: Epilepsia. 1994 Nov-Dec;35(6):1230-43
references.pmid: 7988516
references.citation: Pharmacoeconomics. 2003;21(5):315-26
references.pmid: 12627985
references.citation: Epilepsia. 1998;39 Suppl 3:S19-25
references.pmid: 9593232
references.citation: Seizure. 1998 Apr;7(2):119-25
references.pmid: 9627202
references.citation: Epilepsia. 2000;41 Suppl 5:S37-44
references.pmid: 11045437
references.citation: Seizure. 1999 Feb;8(1):8-13
references.pmid: 10091841
references.citation: Seizure. 1995 Mar;4(1):37-44
references.pmid: 7788105
references.citation: Pharmacoeconomics. 2005;23(5):493-503
references.pmid: 15896100
references.citation: Epilepsia. 2006 Jul;47(7):1094-120
references.pmid: 16886973
references.citation: Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv
references.pmid: 15842952
references.citation: Drugs Today (Barc). 2004 Apr;40(4):325-42
references.pmid: 15190386
references.citation: Lancet. 2007 Mar 24;369(9566):1016-26
references.pmid: 17382828
references.citation: Med Decis Making. 2005 Sep-Oct;25(5):493-510
references.pmid: 16160206
references.citation: Epilepsia. 2002;43 Suppl 4:17-24
references.pmid: 12059997
references.citation: Eur J Health Econ. 2003 Nov;4(4):271-8
references.pmid: 15609195
references.citation: Arch Neurol. 2004 Sep;61(9):1361-5
references.pmid: 15364680
references.citation: Lancet. 2007 Mar 24;369(9566):1000-15
references.pmid: 17382827
references.citation: Seizure. 2007 Jun;16(4):296-304
references.pmid: 17267243
references.citation: Epilepsy Res. 2002 Feb;48(3):207-16
references.pmid: 11904239
references.citation: Epilepsia. 2001 May;42(5):641-6
references.pmid: 11380572
references.citation: Epilepsia. 1997 Aug;38(8):859-80
references.pmid: 9579887
references.citation: Neurology. 1998 Oct;51(4):1026-33
references.pmid: 9781524
references.citation: Ann Neurol. 2001 Mar;49(3):336-44
references.pmid: 11261508
references.citation: Epilepsia. 2004 Feb;45(2):171-8
references.pmid: 14738425
references.citation: Seizure. 1996 Jun;5(2):89-95
references.pmid: 8795122